Abstract 625P
Background
TOS-358 is an oral, highly selective covalent inhibitor of PI3Kα capable of achieving deep, durable inhibition of PI3K-AKT signaling, with virtually no off-target effects. Preclinically, TOS-358 showed anti-cancer activity superior to non-covalent compounds targeting PI3Kα in patient (pt)-derived xenograft models, including breast (BC), colorectal (CRC), head and neck (SCCHN), bladder, and esophageal cancers.
Methods
TOS-358-001 is a dose escalation (phase 1a), dose expansion (phase 1b) study evaluating safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of TOS-358. Eligible pts with specific tumors expressing PIK3CA mutation or amplification, adequate organ function without indication/history of diabetes, ECOG PS 0-1, and no prior treatment with PI3K, AKT or mTOR inhibitors (except pts with BC). The phase 1a was a 3+3 escalation to identify a minimum effective dose (MED) and a maximum tolerated dose (MTD) of TOS-358 when taken once daily (QD) or twice daily (BID). Tumor response was evaluated every 8 weeks by RECIST 1.1. PK was analyzed by non-compartmental analysis. PD was assessed by a TOS-358-specific target engagement assay.
Results
As of April 2024, 28 pts (19 CRC, 1 ovarian, 2 non-small cell lung cancer, 1 endometrial, 1 ovarian, 1 SCCHN, 3 BC) received TOS-358 in 6 cohorts (10 to 30 mg QD, 5 to 15 mg BID). The QD MTD was 20 mg. No MTD has been reached with BID dosing. PK was dose-proportional, and concentrations were within target range. Target engagement >90% was observed at all dose levels, and no MED has been identified thus far. Adverse events were mostly low-grade, dose-dependent, and manageable without dose reduction. Initial monotherapy clinical activity has been observed at multiple dose levels across several PIK3CA-mutant cancer subtypes.
Conclusions
Phase 1a data support covalent inhibition of PI3Kα using TOS-358 as a promising therapeutic that can achieve anti-tumor effects at low doses with minimal toxicity. A phase 1b study evaluating the combination of TOS-358 and fulvestrant in HER2- breast cancer pts and TOS-358 monotherapy in bladder cancer pts is planned to initiate in 2H of 2024.
Clinical trial identification
NCT05683418; Release date: January 13, 2023.
Editorial acknowledgement
Legal entity responsible for the study
Totus Medicines Inc.
Funding
Totus Medicines Inc.
Disclosure
M. Fakih: Financial Interests, Personal, Advisory Board, Consultant: AbbVie, Inc., AstraZeneca, Bayer Corporation; Financial Interests, Personal, Advisory Board, Consultant/One Meeting: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board, One meeting: Eisai Oncology; Financial Interests, Personal, Advisory Board, One meeting: Entos, Seattle Genetics, Xenthera; Financial Interests, Personal, Advisory Board, One Meeting: Janssen; Financial Interests, Personal, Advisory Board: Merck, Nouscom, Roche / Genentech; Financial Interests, Personal, Advisory Board, Also Editorial Boards & Consulting: Mirati Therapeutics; Financial Interests, Personal, Advisory Board, Consulting/One Meeting: Pfizer; Financial Interests, Personal, Advisory Board, Consulting: Taiho Oncology; Financial Interests, Institutional, Research Grant: AgenusBio, Genentech / imCORE, Verastem. D. Sohal: Financial Interests, Personal, Invited Speaker: InCyte, SeaGen, AstraZeneca; Financial Interests, Personal, Advisory Board: Totus, Regeneron, Elevar; Financial Interests, Institutional, Trial Chair: Ability Pharma, AstraZeneca; Financial Interests, Institutional, Local PI: Amgen, Apexigen, Astellas, Bexion, BMS, FibroGen, Genentech, Hengrui, Merck, Mirati, NextCure, PanCAN, Regeneron, Roche. A.B. El-Khoueiry: Financial Interests, Personal, Advisory Board: Exelixis, AstraZeneca, Genentech, Agenus, Tallac, ABL Bio, Senti Biosciences, Qurient; Financial Interests, Institutional, Funding: Fulgent, Astex, AstraZeneca; Financial Interests, Personal, Steering Committee Member: Merck, Genentech; Financial Interests, Personal, Coordinating PI: Genentech; Financial Interests, Institutional, Coordinating PI, trial; funding: Auransa; Non-Financial Interests, Principal Investigator: Agenus, Affimed, Bayer. A.I. Spira: Financial Interests, Personal, Other, Consulting or Advisory Role: Incyte, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi Sankyo/AstraZeneca, Array Biopharma, Blueprint Medicines, Regeneron, Lilly, Black Diamond Therapeutics, Sanofi; Financial Interests, Personal, Other, Consulting or Advisory Role / Honoraria: Amgen, Novartis, Takeda, AstraZeneca/MedImmune, Merck, Bristol Myers Squibb; Financial Interests, Personal, Other, Honoraria: CytomX Therapeutics, Janssen Oncology, Bayer; Financial Interests, Institutional, Officer, CEO: NEXT Oncology Virginia; Financial Interests, Personal, Stocks/Shares: Eli Lilly; Financial Interests, Institutional, Local PI: LAM Therapeutics, Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Newlink Genetics, Incyte, AbbVie, Ignyta, Trovagene, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol Myers Squibb, Loxo, Arch Therapeutics, Gritstone, Plexxikon, Amgen, Daiichi Sankyo, ADCT, Janssen Oncology, Mirati Therapeutics, Rubius, Synthekine, Mersana, Blueprint Medicines, Kezar, Revolution Med, Regeneron, Loxo, Alkermes, Medikine, Black Diamond Therapeutics, Nalo Therapeutics, Scorpion Therapeutics, Arrivent Biopharma, GV20 Therapeutics. H. Merrit, K. Hari: Financial Interests, Institutional, Full or part-time Employment: Totus Medicines. O.C. Trifan: Financial Interests, Personal, Stocks or ownership: Totus Medicines. N. Dhawan: Financial Interests, Personal and Institutional, Full or part-time Employment: Totus Medicines. All other authors have declared no conflicts of interest.
Resources from the same session
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01
639P - Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Presenter: Sophie Cousin
Session: Poster session 01
640P - Tumor response rate for hematologic and solid cancer drugs with FDA approval supported by single-arm trials
Presenter: Daniel Michaeli
Session: Poster session 01